ESG News Review 13 — 20 July 2013
GlaxoSmithKline continued to be the most criticized company last week, as Chinese officials pursued their investigation into the suspected "economic crimes" of executives, including bribery. This affair occupies a large portion of the summer media space. On the other hand,…